Analyst Price Targets — GMAB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 23, 2026 11:31 am | Michael Schmidt | Guggenheim | $40.00 | $29.29 | TheFly | Genmab price target lowered to $40 from $45 at Guggenheim |
| February 17, 2026 9:26 am | Benjamin Jackson | Jefferies | $41.50 | $30.03 | TheFly | Genmab resumed with a Buy at Jefferies |
| January 20, 2026 11:18 am | — | H.C. Wainwright | $39.00 | $32.25 | TheFly | Genmab price target lowered to $39 from $41 at H.C. Wainwright |
| November 6, 2025 8:03 pm | Asthika Goonewardene | Truist Financial | $48.00 | $28.84 | StreetInsider | Genmab A/S (GMAB) PT Lowered to $48 at Truist Securities |
| October 6, 2025 11:12 am | Asthika Goonewardene | Truist Financial | $49.00 | $33.56 | TheFly | Genmab price target raised to $49 from $46 at Truist |
| October 2, 2025 12:52 pm | — | H.C. Wainwright | $40.00 | $31.77 | TheFly | Genmab price target raised to $40 from $36 at H.C. Wainwright |
| September 29, 2025 5:04 pm | Jonathan Chang | Leerink Partners | $34.00 | $29.16 | TheFly | Genmab price target raised to $34 from $32 at Leerink |
| September 23, 2025 11:41 am | Michael Schmidt | Guggenheim | $43.00 | $28.60 | TheFly | Genmab upgraded to Buy from Neutral at Guggenheim |
| March 11, 2025 1:55 pm | Asthika Goonewardene | Truist Financial | $45.00 | $20.26 | TheFly | Genmab price target lowered to $45 from $50 at Truist |
| September 4, 2024 1:56 am | Vikram Purohit | Morgan Stanley | $31.00 | $27.41 | StreetInsider | Morgan Stanley Resumes Genmab A/S (GMAB) at Equalweight |
Latest News for GMAB
Company Announcement COPENHAGEN, Denmark; March 2, 2026 – Genmab A/S (Nasdaq: GMAB) - Correction: In Company Announcement no. 13/2026 regarding transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons it was reported that the share price associated with these transactions was DKK 0,00.
Company Announcement COPENHAGEN, Denmark; March 2, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.
Company Announcement COPENHAGEN, Denmark; March 2, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum aggregate total value of DKK 725 million to honor our commitments under the Restricted Stock Unit program.
Pre-Market Stock Futures: The futures are trading lower after a dreadful Friday and week, one that could be laying the foundation for a larger and more intense sell-off. The combination of the sell-off in Nvidia Corp. (NASDAQ: NVDA), the much higher producer price index print, the ongoing confusion over the tariffs, and the weekend military... Here Are Monday's Top Wall Street Analyst Research Calls: AppLovin, Blue…
Company Announcement COPENHAGEN, Denmark; February 27, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for GMAB.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.